These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 15593036

  • 1. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW, Chang CH.
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [Abstract] [Full Text] [Related]

  • 3. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
    Kessler M, Hannedouche T, Fitte H, Cayotte JL, Urena P, Réglier JC, Groupe de l'étude NESP 20000117.
    Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, Wagener T, German Aranesp Study Group.
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [Abstract] [Full Text] [Related]

  • 5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 May; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ, European/Australian NESP 970200 Study Group.
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P.
    Am J Nephrol; 2006 Dec; 26(2):149-56. PubMed ID: 16636531
    [Abstract] [Full Text] [Related]

  • 8. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ.
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [Abstract] [Full Text] [Related]

  • 9. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J.
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH, Holzer H, Mayer GJ, Osterreichische Aranesp Studiengruppe.
    Wien Klin Wochenschr; 2002 Dec 30; 114(23-24):967-71. PubMed ID: 12635463
    [Abstract] [Full Text] [Related]

  • 11. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr 30; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
    Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK.
    Mayo Clin Proc; 2006 Sep 30; 81(9):1188-94. PubMed ID: 16970215
    [Abstract] [Full Text] [Related]

  • 13. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb 30; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 14. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Feb 30; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S, KRN321 A09 Study Group.
    Ther Apher Dial; 2008 Feb 30; 12(1):19-27. PubMed ID: 18257808
    [Abstract] [Full Text] [Related]

  • 16. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct 30; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Oct 30; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 18. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
    Mirtsching B, Charu V, Vadhan-Raj S, Colowick AB, Rossi G, Tomita D, McGuire WP.
    Oncology (Williston Park); 2002 Oct 30; 16(10 Suppl 11):31-6. PubMed ID: 12435171
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 30; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 20. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
    Li WY, Chu TS, Huang JW, Wu MS, Wu KD.
    J Formos Med Assoc; 2008 Nov 30; 107(11):843-50. PubMed ID: 18971153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.